The NIH intramural research program has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.

SARS-CoV-2 Vaccine Clinical Trials Using ACTIV-Informed Harmonized Protocols

ACTIV advised on the protocol designs and endpoints to ensure a harmonized approach across multiple vaccine efficacy trials. The protocol enables analyses of correlates of protection across several vaccine trials being implemented under Operation Warp Speed and activated at sites that are part of the NIH COVID-19 Prevention Network.

As vaccine clinical trials using these harmonized protocols are launched, NIH will list those studies this page.

SARS-CoV-2 Vaccine Clinical Trials Using

Harmonized Protocols Informed by ACTIV

photo of a doctor giving an injection to a patient
Agent Trial Phase Description More Information

mRNA-1273

Phase 3

An investigational vaccine to evaluate prevention of symptomatic COVID-19 in adults. The vaccine was co-developed by Moderna, Inc., and NIAID.

This page last reviewed on August 4, 2020